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Abstract
Objectives:  To  characterize  the  clinical,  laboratory,  and  anthropometric  proﬁle  of  a  sample  of
Brazilian  patients  with  glycogen  storage  disease  type  I  managed  at  an  outpatient  referral  clinic
for  inborn  errors  of  metabolism.
Methods: This  was  a  cross-sectional  outpatient  study  based  on  a  convenience  sampling  strategy.
Data on  diagnosis,  management,  anthropometric  parameters,  and  follow-up  were  assessed.
Results:  Twenty-one  patients  were  included  (median  age  10  years,  range  1--25  years),  all  using
uncooked  cornstarch  therapy.  Median  age  at  diagnosis  was  7  months  (range,  1--132  months),Nutritional  status
and  19  patients  underwent  liver  biopsy  for  diagnostic  conﬁrmation.  Overweight,  short  stature,
hepatomegaly,  and  liver  nodules  were  present  in  16  of  21,  four  of  21,  nine  of  14,  and  three
of  14  patients,  respectively.  A  correlation  was  found  between  height-for-age  and  BMI-for-age
Z-scores  (r  =  0.561;  p  =  0.008).
 Please cite this article as: Santos BL, de Souza CF, Schuler-Faccini L, Refosco L, Epifanio M, Nalin T, et al. Glycogen storage disease type
: clinical and laboratory proﬁle. J Pediatr (Rio J). 2014;90:572--9.
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Conclusions:  Diagnosis  of  glycogen  storage  disease  type  I  is  delayed  in  Brazil.  Most  patients
undergo liver  biopsy  for  diagnostic  conﬁrmation,  even  though  the  combination  of  a  character-
istic  clinical  presentation  and  molecular  methods  can  provide  a  deﬁnitive  diagnosis  in  a  less
invasive  manner.  Obesity  is  a  side  effect  of  cornstarch  therapy,  and  appears  to  be  associated
with growth  in  these  patients.
© 2014  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  
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Doenc¸a  de  depósito  de  glicogênio  tipo  I:  perﬁl  clínico  e  laboratorial
Resumo
Objetivos:  Caracterizar  o  perﬁl  clínico,  laboratorial  e  antropométrico  de  uma  amostra  de
pacientes brasileiros  com  doenc¸a de  depósito  de  glicogênio  tipo  I  tratados  em  um  ambulatório
de referência  para  erros  inatos  do  metabolismo.
Métodos:  Este  foi  um  estudo  ambulatorial  transversal  com  base  em  uma  estratégia  de
amostragem de  conveniência.  Foram  avaliados  os  dados  com  relac¸ão  ao  diagnóstico,  trata-
mento,  parâmetros  antropométricos  e  acompanhamento.
Resultados:  Foram  incluídos  21  pacientes  (idade  média  de  10  anos,  faixa  1-25  anos  de  idade),
e todos  se  encontravam  em  terapia  de  amido  de  milho  cru.  A  idade  média  na  época  do  diagnós-
tico  foi  de  sete  meses  (faixa,  1-32  meses),  e  19  pacientes  foram  submetidos  a  biópsia  hepática
para  conﬁrmac¸ão  do  diagnóstico.  Sobrepeso,  baixa  estatura,  hepatomegalia  e  nódulos  hepáti-
cos  foram  fatores  presentes  em  16  de  21,  quatro  de  21,  nove  de  14  e  três  de  14  pacientes,
respectivamente. Foi  encontrada  uma  correlac¸ão  entre  os  escores  z  para  peso  para  idade  e  IMC
para  idade  (r  =  0,561;  p  =  0,008).
Conclusões:  O  diagnóstico  da  doenc¸a de  depósito  de  glicogênio  tipo  I  tem  sido  tardio  no  Brasil.
A maioria  dos  pacientes  foi  submetida  a  conﬁrmac¸ão  do  diagnóstico,  apesar  de  o  quadro  clínico
característico  e  os  métodos  moleculares  poderem  fornecer  um  diagnóstico  deﬁnitivo  de  forma
menos  invasiva.  Obesidade  é  um  efeito  colateral  da  terapia  com  amido  de  milho  e  parece  estar
associada  a  crescimento  nesses  pacientes.
©  2014  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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Glycogen  storage  disease  type  I  (GSDI,  or  von  Gierke’s
disease) is  caused  by  deﬁciency  of  glucose-6-phosphatase
(G6Pase),  an  enzyme  that  catalyzes  hydrolysis  of  glucose-6-
phosphate (G6P)  into  glucose  and  inorganic  phosphate  (Pi),
a key  step  in  the  maintenance  of  glucose  homeostasis.  Two
major subtypes  of  GSDI  are  recognized:  GSD  type  Ia  (GSDIa),
which is  the  result  of  a  mutation  affecting  the  catalytic  sub-
unit of  G6Pase-alpha  (or  G6PC),  and  GSD  type  Ib  (GSDIb),
which is  caused  by  a  defect  in  G6P  translocase  (or  G6PT).1
GSDI  is  inherited  in  an  autosomal  recessive  pattern,  and  its
incidence is  estimated  at  one  in  100,000  live  births,  making
it the  most  common  of  the  hepatic  GSDs.2
Patients  with  GSDIa  present  with  hepatomegaly,  a  char-
acteristic ‘‘doll-like’’  face,  short  stature,  and  chronic
fatigue. Laboratory  ﬁndings  suggestive  of  GSDIa  include
hypoglycemia after  a  four  to  six  hour  fast,  lactic  acidosis,
hypertriglyceridemia, and  hyperuricemia.  Functional  tests
for differential  diagnosis  of  hypoglycemia  show  absence  of
glycemic response  to  glucagon  injection  and  aggravation
3of hyperlactacidemia, whereas  histopathological  analysis
of hepatic  biopsy  specimens  shows  glycogen  buildup  in  the
liver. In  GSDIb,  the  clinical  presentation  is  quite  similar  to
that of  GSDIa,  but  may  be  accompanied  by  neutropenia
m
i
nith  recurrent  infections  (particularly  of  the  gastrointesti-
al tract)  and  an  increased  incidence  of  inﬂammatory  bowel
isease.4 Although  the  gold-standard  methods  for  diagnosis
f GSDIa  are  the  measurement  of  G6PC  or  G6PT  activity  in
iver tissue  and/or  detection  of  pathogenic  mutations  in  the
enes that  code  for  G6PC  and  G6PT,  speciﬁc  therapy  can  be
nitiated based  solely  on  the  clinical  and  histopathological
ndings.3 Access  to  the  DNA/enzyme  tests  is  limited  since
hey are  only  provided  by  a  select  few  national  and  inter-
ational centers,  usually  within  the  framework  of  research
rojects.
Management of  GSDI  is  essentially  dietary,3 and  con-
ists of  frequent  meals  --  preferably  containing  slow-release
arbohydrates such  as  uncooked  cornstarch  --  at  regular
ntervals, and  restriction  of  fructose,  sucrose,  and  lac-
ose intake.  In  infants,  the  recommended  management
trategy includes  frequent  meals  and  continuous  nocturnal
nfusion of  glucose  at  a  rate  of  6-8  mg/kg/min  through  a
asogastric or  gastrostomy  tube.  Treatment  efﬁcacy  is  mea-
ured by  monitoring  growth  and  biochemical  parameters,
s well  as  by  abdominal  ultrasound  for  assessment  of  liver
olume and  presence  of  nodules.  Proper  dietary  manage-
ent decreases  the  risk  of  long-term  complications,  which
nclude short  stature,  osteoporosis  or  bone  mineral  loss,  kid-
ey disease  with  hypertension,  proteinuria,  renal  calculi,
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ephrocalcinosis,  hepatocellular  adenomas  (with  poten-
ial for  malignant  transformation),  pancreatitis  secondary
o hypertriglyceridemia,  and  potentially  life-threatening
ypoglycemia.5,6
The  objective  of  this  study  was  to  assess  the  clinical
nd laboratory  proﬁle  of  a  sample  of  Brazilian  patients  with
SDI recruited  from  an  outpatient  referral  center  for  inborn
rrors of  metabolism.  The  main  research  hypothesis  was  that
iagnosis of  GSDI  is  delayed  in  Brazil,  both  due  to  a  lack  of
ccess to  diagnostic  methods  and  due  to  poor  awareness  of
he condition  by  healthcare  providers,  thus  hindering  early
ccess to  speciﬁc  treatment  and  genetic  counseling.
ethods
his  study  was  approved  by  the  Ethics  Committee  of  Hospital
e Clínicas  de  Porto  Alegre  (HCPA,  Brazil).  All  subjects  signed
n informed  consent  prior  to  study  participation.
This  was  an  outpatient-based  case  series  with  cross-
ectional analysis  of  the  variables  of  interest.  A  convenience
ampling strategy  was  used.  The  study  was  conducted
etween March  of  2011  and  January  of  2013.  The  cri-
erion for  inclusion  was  a  diagnosis  of  GSDI  established
sing at  least  two  of  the  following  methods  (the  diag-
osis was  independently  conﬁrmed  by  the  authors  in
ll patients):  a)  clinical  diagnosis,  deﬁned  by  over  12
onths of  specialist  care  (led  by  hepatologist  or  medical
eneticist) and  clinical  manifestations  consistent  with  GSDI
hypoglycemia with  hyperlactatemia,  hypertriglyceridemia,
yperuricemia,  hepatomegaly,  and/or  growth  failure  and
hort stature,  and  normal  levels  of  creatine  phosphoki-
ase [CPK])  at  the  time  of  diagnosis  or  at  the  time  of
tudy inclusion;  b)  positive  family  history  consistent  with
utosomal recessive  inheritance,  as  long  as  GSDI  had  been
onﬁrmed by  enzymatic  methods  or  DNA  analysis  in  the
ffected relative(s);  c)  histopathological  diagnosis,  deﬁned
s the  presence  of  histological  changes  in  liver  tissue  con-
istent with  GSD,  such  as  hyperglycogenated  nuclei,  mild
brosis, and  fatty  changes  with  lipid  vacuoles;7 d)  enzymatic
iagnosis, deﬁned  by  negligible  activity  (<  10%)  of  G6Pase  in
resh or  frozen  liver  tissue  samples;  or  e)  molecular  diagno-
is, deﬁned  by  the  presence  of  pathogenic  mutations  in  the
6PC gene  (for  patients  with  GSDIa)  or  in  the  SLC37A3 gene
for those  with  GSDIb)  as  detected  by  molecular  methods.
he distinction  between  GSDIa  and  GSDIb  was  mostly  based
n clinical  ﬁndings  (absence  or  presence  of  neutropenia,
espectively), as  molecular  diagnostics  were  unavailable  to
he majority  of  patients.
Patients  were  invited  to  take  part  in  the  study  after  rou-
ine visits.  Those  who  agreed  to  participate  were  all  assessed
y the  same  researcher  and  underwent  a  targeted  history,
hysical examination,  and  anthropometric  assessment.  The
atest laboratory  values  (blood  glucose,  lactate,  cholesterol,
riglycerides, uric  acid)  and  imaging  ﬁndings  available  for
ach patient  were  obtained  by  means  of  a  chart  review.
ests performed  up  to  three  months  prior  to  anthropomet-
ic assessment  were  considered  acceptable.  The  variables  of
nterest were  sex,  parental  consanguinity,  current  age,  age
t  diagnosis  (deﬁned  as  the  age  at  which  parents  reported  a
peciﬁc diagnosis  of  GSD  or,  if  unavailable,  the  age  at  diagno-
is as  noted  in  the  patient’s  ﬁrst  chart  containing  diagnostic
1
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est  results  and  start  of  dietary  management),  ﬁrst  clinical
anifestation (as  reported  by  parents),  laboratory  param-
ters (current  and  at  time  of  diagnosis),  liver  biopsy  for
istopathological examination  or  molecular  analysis,  and
urrent clinical  and  imaging  data  (anthropometric  assess-
ent, liver  ultrasound,  and  bone  mineral  density  and  body
omposition by  dual-energy  X-ray  absorptiometry  [DEXA]).
Anthropometric  assessment  consisted  of  weight  (kg)  and
eight (cm)  measurement.  Body  weight  was  measured  using
igital scales  with  a  maximum  capacity  of  150  kg  and  a  reso-
ution of  100  g,  certiﬁed  by  the  Brazilian  National  Institute  of
etrology, Standardization,  and  Industrial  Quality  (Instituto
acional de  Metrologia,  Qualidade  e  Tecnologia  -  INMETRO).
atients were  weighed  while  nude  and  barefoot.  Height  was
easured with  a  wall-mounted  stadiometer  precise  to  1  mm.
n adolescents,  the  Tanner  scale  was  used  for  pubertal  stag-
ng. Anthropometric  measurements  and  classiﬁcations  for
ge and  sex  were  calculated  in  the  World  Health  Organi-
ation’s AnthroPlus  software  suite.  The  variables  of  interest
ere height-for-age  and  BMI-for-age  Z-scores,  as  proposed
y the  Brazilian  Society  of  Pediatrics.8
Liver  size  was  measured  by  ultrasonography  and  assessed
or normality  on  the  basis  of  the  reference  sizes  for  children
ublished in  2010  by  Dhingra  et  al.9 When  objective  data  on
iver size  were  missing,  the  sonographer’s  impression  was
sed instead  (normal  or  enlarged).
The  criteria  for  adequacy  of  metabolic  control  were
ased on  the  European  Study  on  Glycogen  Storage  Disease
ype 1  (ESGSD  I):5 blood  glucose  >  63  mg/dL,  triglyceri-
es <  530  mg/dL,  uric  acid  <  7  mg/dL,  BMI  between  0  and  +  2
tandard deviations  (SD),  and  lactate  >  2.5  mmol/L  (the
atter used  as  the  urine  lactate/creatinine  ratio  was  unavail-
ble). The  absence  of  hepatic  adenomas  and  adequate
eight-for-age (z-score  >  -2  SD)  are  important  parameters
or assessment  of  metabolic  control  adequacy,  but  are  not
art of  the  ESGSD  I.5
Statistical  analyses  were  conducted  in  the  Statistical
ackage for  the  Social  Sciences®  version  20.0  (SPSS  Inc.,
hicago, IL,  USA).  Continuous  variables  were  expressed  as
eans and  standard  deviations  or  as  medians  and  interquar-
ile ranges.  Analysis  of  variance  (ANOVA)  was  used  for
omparison of  height  and  BMI  z-scores.  The  signiﬁcance  level
as set  at  5%.  Data  were  entered  into  a  Microsoft  Excel  2010
or Windows  spreadsheet  (Microsoft,  Redmond,  WA,  EUA)
nd analyzed  in  SPSS  20.0  (IBM  Corp.,  Armonk,  NY,  USA).
esults
wenty-one  patients  were  included  in  the  study:  17  with
SDIa and  four  with  GSDIb.  Table  1  shows  the  sample  proﬁle
t the  time  of  diagnosis.
Table 2  presents  the  anthropometric  and  laboratory  data,
s well  as  compliance  with  uncooked  starch  therapy.  Six-
een patients  had  excess  body  weight  (six  of  21  severely
bese [BMI-for-age  zscore  > +  3];  six  of  21  obese;  four  of  21
verweight). The  mean  BMI-for-age  z-score  was  2.19  (1.5
o 2.8),  and  the  mean  height-for-age  z-score  was  -1.16  (-
.76 to  -0.58);  four  of  21  patients  had  short  stature,  one
f whom  had  very  short  stature  (z-score  <  -3).  Fig.  1  pro-
ides a  graphical  representation  of  the  positive,  signiﬁcant
orrelation between  height  and  BMI  z-scores.
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Table  1  Summary  of  ﬁndings  at  diagnosis  among  patients  with  glycogen  storage  disorder  (GSD)  type  I  (n  =  21).
Patient Sex  GSD
Type
Consanguinity  Age  at
diagnosis
(months)
Initial clinical
manifestation
Method  of  GSD
diagnosis
Lactateb
mmol/L
Triglyceridesb
mg/dL
Cholesterolb
mg/dL
Glucoseb
mg/dL
Uric
acidb
mg/dL
AST/
ALTb
1  F  Ia  +  12  N/A  Enzyme  +  clinical 10.1  573  259  36  9.8  137/126
2 F  Ia  +  7  Metabolic
acidosis
Enzyme  +  clinical
+ DNA
4.75  1101  262  <  60 3.4  971/182
3 F  Ia  +  24  Hepatomegaly  Enzyme  +  clinical
+ DNA
12.5  714  214  <  60 7.5  N/A
4 M  Ia  -  9  Hypoglycemia  Histopathology  +
clinical
N/A 1646  581  113  N/A  375/348
5a F  Ia  +  1  Hypoglycemia  Family  history  +
clinical
7.81  719  N/A  31  N/A  N/A
6a F  Ia  +  6  Hypoglycemia  Enzyme  +  clinical 7  2013  226  57  3  142/102
7 M  Ia  -  5  Hepatomegaly  Enzyme  +  clinical 4.6  143  155  116  3.4  31/40
8 M  Ia  +  4  Seizure  Enzyme  +  clinical
+ DNA
N/A  216  161  0  6.7  48/23
9 M  Ia  -  7  Hepatomegaly  Enzyme  +  clinical 1.7  366  231  77  6  26/25
10 M  Ia  -  36  Hypoglycemia  Enzyme  +  clinical  N/A  1695  285  48  6.3  34
11 M  Ia  -  4  Hepatomegaly  Clinical  +  DNA  4.4  836  318  N/A  8.1  N/A
12 F  Ia  -  48  Hepatomegaly  Enzyme  +  clinical  10.25  610  185  45  9  59/45
13 M  Ia  +  3  Hypoglycemia  Enzyme  +  clinical  N/A  218  187  98  95/63
14 M  Ia  +  132  Short  stature  Enzyme  +  clinical  8.2  941  317  61  10  56/69
15 M  Ia  -  7  Hepatomegaly  Enzyme  +  clinical
+ DNA
N/A  940  388  32  7.3  157/130
16 F  Ia  -  84  Hepatomegaly  Histopathology  +
clinical
7.9 918  N/A  56  7.2  N/A
17 F  Ia  -  15  Hepatomegaly  Histopathology  +
Clinical
6 355  308  53  5.5  33/19
18 M  Ib  +  6  Hypoglycemia  Enzyme  +  Clinical  2.8  371  N/A  86  10.1  N/A
19 F  Ib  -  4  Recurrent
infections
Histopathology  +
Clinical
1.6 266  N/A  143  8.9  N/A
20 M  Ib  -  6  Hypoglycemia  Enzyme  +  Clinical  N/A  123  107  N/A  4.5  26/22
21 F  Ib  -  6  Hypoglycemia  Clinical  +  DNA  5.3  715  196  93  6.6  51/41
All patients had clinical manifestations at the time of diagnosis or were in treatment with a pediatric gastroenterologist or medical geneticist at the time of study inclusion and had
histopathological evidence of hepatic glycogen buildup and/or G6Pase activity at < 10% in liver tissue and/or presence of pathogenic mutations in the G6Pase gene, and absence of high
levels of creatine phosphokinase.
AST,  aspartate aminotransferase; ALT, alanine aminotransferase.
a Patients 5 and 6 form a Sibship; patient 6 is the older sibling.
b Values at diagnosis; +, present; -, absent; N/A, not available. Reference ranges: lactate, 0.5--2.2 mmol/L; triglycerides, 100 mg/dL at age <10 years, ≤ 130 mg/dL at age 10--19,
≤ 150 mg/dL in adults; total cholesterol, <129 mg/dL; glucose, 60--99 mg/dL; uric acid, 2.4--7 mg/dL; AST, < 37 mg/dL; ALT, < 41 mg/dL.
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Table  2  Last  anthropometric  and  laboratory  assessment  of  patients  with  glycogen  storage  disorder  type  I  (n  =  21).
Patient  Age
(years)
Cornstarcha
(g/kg/dose)
Weight
(kg)
Height
(cm)
Height
Z-score
BMI  BMI
Z-score
Stage  of
puberty
Lactate
(mmol/L)
Triglycerides
(mg/dL)
Cholesterol
(mg/dL)
Glucose
(mg/dL)
Uric  acid
(mg/dL)
Bone  density  scan
Z-score  BF%
1  13  2.5  32.4  130.5  -4.1  19.02  -0.13  Prepubertal  4.5  555  N/A  100  4.6  -3.1  33.2
2 5  2.1  18.9  100.5  -2.06  18.71  1.91  Prepubertal  1.6  83  101  101  4  -1.4  46.1
3 4  2.5  17.8  102.8  -1.18  16.84  0.99  Prepubertal  3.1  192  N/A  96  4.3  N/A  N/A
4 6  1  30.2  111.5  -0.95  24.29  4.64  Prepubertal  5.5  1071  242  151  5.2  -0.4  45
5 16  1.3  64.7  154  -2.46  27.28  1.88  Pubertal  2.5  276  214  52  7.6  N/A  N/A
6 17  0.6  77  150.9  -1.73  33.82  2.72  Pubertal  2.3  211  179  65  7.6  N/A  N/A
7 9  0.5  74.3  146.5  2.47  34.62  5.66  Prepubertal  0.3  N/A  115  65  2.7  N/A  N/A
8 17  1  70  161.5  -1.84  26.84  1.6  Pubertal  1  242  156  87  6.4  -1  41.3
9 21  1.3  66.9  168.5  -1.1  23.56  0.46  Adult  1.4  192  240  N/A  5.4  -1.4  22.2
10 25  1  60.3  170.5  -0.82  20.70  -0.52  Adult  6.2  809  264  92  N/A  N/A  N/A
11 20  1.4  72  170  -0.89  24.91  0.86  Adult  2.2  488  262  48  6.6  0.9  27.8
12 10  1.35  44.3  138  -0.17  23.26  2.13  Prepubertal  2.7  454  N/A  90  8.5  N/A  N/A
13 6  1.9  25.9  113.2  -1.44  20.21  2.56  Prepubertal  N/A  218  187  98  N/A  -1.3  33.9
14 16  0.8  99.3  164.5  -1.21  36.70  3.26  Pubertal  1.5  404  273  94  9  N/A  N/A
15 7  1.6  36.5  130  0.73  21.60  2.74  Prepubertal  1.6  192  N/A  85  3.9  N/A  N/A
16 10  0.8  51.9  140  0.21  26.50  2.73  Prepubertal  1.8  218  233  69  7.1  N/A  N/A
17 4  1  22.5  102.5  -1.14  21.42  3.19  Prepubertal  9.8  321  237  25  7.6  N/A  31.7
18 12  1.1  56.7  136.5  -1.92  30.43  3.02  Prepubertal  2.8  371  N/A  86  10.1  -0.6  46.2
19 11  1.6  34.4  130  -2.4  20.30  1.09  Prepubertal  0.8  159  129  86  7.1  N/A  N/A
20 7  0.9  28.7  118.5  -0.98  20.44  2.47  Prepubertal  0.5  123  107  93  3.6  0.6  30.6
21 1 b 11.9  75  -1.29  21.16  3.08  Prepubertal  5.3  715  196  93  6.6  N/A  N/A
BMI, body mass index.
a All patients were on uncooked starch therapy (four to six times/day) and none were on continuous nocturnal glucose infusion.
b Patient who received cornstarch irregularly.
Height-for-age and BMI-for-age Z-scores calculated in World Health Organization’s Anthro and AnthroPlus. Bone density scanning performed in a Lunar iDXA (GE Healthcare) device. Bone
mineral density Z-scores calculated and body composition expressed as body fat percentage (BF%). Bone mineral density Z-scores not calculated for patient 17 due to age < 5 years. N/A,
not available.
Reference ranges: lactate, 0.5--2.2 mmol/L; triglycerides, ≤ 100 mg/dL at age < 10 years, ≤ 130 mg/dL at age 10--19, ≤ 150 mg/dL in adults; total cholesterol, < 129 mg/dL; glucose,
60--99 mg/dL; uric acid, 2.4--7 mg/dL.
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Figure  1  Correlation  between  BMI-for-age  and  height-for-age
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BMI, body  mass  index.
Body  composition  was  analyzed  in  ten  patients  (eight
with GSDIa,  two  with  GSDIb)  (Table  2).  Fourteen  patients
underwent abdominal  ultrasonography  for  assessment  of
liver size;  of  these,  ﬁve  had  a  normal  liver  size,  one  of  whom
had a  visible  hepatic  nodule.  The  eight  remaining  patients
had hepatomegaly,  and  two  had  more  than  three  detectable
nodules.
Discussion
The  characterization  of  the  natural  history  of  rare  diseases
and of  the  efﬁcacy  of  treatments  for  these  conditions  is
always hindered  by  small  sample  sizes.10 The  small  num-
ber of  patients  is  attributable  not  only  to  the  rarity  of  these
diseases, but  also  to  underdiagnosis,  particularly  of  cases
with relatively  mild  clinical  manifestations.  Therefore,  stud-
ies such  as  the  present  --  the  ﬁrst-ever  characterization
of a  population  of  GSDI  patients  in  Brazil  are  paramount,
given their  crucial  role  in  enabling  later  conduction  of  meta-
analysis and  the  drawing  of  more  robust  conclusions.
Diagnosis  of  GSDI  was  delayed  in  this  sample,  conﬁrming
the initial  hypothesis.  According  to  the  literature,  the  usual
age of  symptom  onset  in  patients  with  GSDI  is  3  months.4 This
study did  not  assess  the  variable  ‘‘age  at  symptom  onset’’
as the  authors  believe  it  to  be  subject  to  a  wide  range  of
biases, particularly  recall  bias.  Studies  have  shown  that  ear-
lier diagnosis  and  treatment  onset  are  associated  with  lower
odds of  complications.3 In  the  present  sample,  the  earli-
est clinical  diagnosis  was  established  in  a  patient  (patient
5) who  developed  symptoms  before  the  1st  month  of  life,
who had  an  older  sister  (patient  6)  with  a  conﬁrmed  diag-
nosis of  GSDIa.  The  latest  diagnosis  was  at  132  months  of
age, in  patient  14,  who  had  subclinical  hypoglycemia  and
was diagnosed  after  a  three  year  investigation  prompted
by short  stature,  thus  representing  a  somewhat  attenuated
phenotype of  the  condition.  Although  hypoglycemia  is  one  of
the cardinal  symptoms  that  drive  clinical  suspicion  of  GSDI,
it may  sometimes  go  unnoticed  due  to  use  of  lactic  acid
as a  substrate  for  cerebral  metabolism.11 Therefore,  even
though symptomatic  hypoglycemia  is  frequently  reported,
its absence  does  not  rule  out  a  diagnosis  of  GSDI.  In  2003,
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hieh  et  al.  published  a  case  report  describing  delayed  diag-
osis of  GSDI  and  suggested  that  ‘‘milder’’  forms  of  the
ondition may  occur.11 Also  in  2003,  an  article  recommended
hat adolescents  with  unexplained  hyperuricemia  and  hyper-
ipidemia should  be  screened  for  GSDI,  even  if  hypoglycemia
as absent.12
Regarding  diagnostic  procedures,  most  patients  in  the
resent sample  underwent  a  liver  biopsy.13 This  ﬁnding  is
ather surprising  in  view  of  the  increased  worldwide  acces-
ibility of  genetic  testing.  The  G6PC  gene  is  small  (12.5  kb,  5
xons) and  thus  easily  sequenced;  furthermore,  the  variants
.347X and  p.R83C  appear  to  be  common  in  the  Brazil-
an population,  as  reported  by  Reis  et  al.  in  2011.14 In
he present  sample,  these  mutations  were  found  in  four
f ten  and  three  of  ten  patients  with  GSDIa,  respectively
data not  shown).  Although  it  is  not  entirely  devoid  of  risk,
lood collection  for  genetic  assays  is  a  far  less  invasive  and
ess costly  procedure  than  liver  biopsy  for  histopathological
xamination or  enzyme  activity  assessment.  Isolated  his-
ological analysis  of  liver  tissue  without  measurement  of
nzyme activity  is  not  sufﬁcient  to  determine  the  type  of
SD, although  it  can  demonstrate  glycogen  and  fat  deposi-
ion, and  is  valuable  in  the  differential  diagnosis  of  other
iver diseases.  Conversely,  enzyme  assays  are  available  only
t  very  few  centers  and  are  associated  with  a  series  of
ogistical challenges,  such  as  tissue  transport  (specimens
hould preferably  be  fresh  or  frozen)  to  the  reference
aboratory.
The present  data  suggest  a  trend  toward  patients  with
igher height-for-age  Z-scores  having  higher  BMI-for-age
-scores as  well.15 Although  this  trend  was  affected  by  out-
iers, it  suggests  that  intensive  dietary  management  leads
o better  growth  at  the  expense  of  marked  weight  gain,  as
reviously reported  by  Weinstein  and  Wolfsdorf  in  2002.6
anagement  of  obesity  in  patients  with  GSDI  is  certainly  a
opic deserving  of  greater  research  attention.
Growth  retardation  is  a  ﬁnding  of  major  importance  in
hildren with  GSDI,16 and  short  stature  is  common  in  adults
ith the  condition.  In  the  present  sample,  patients  with
nadequate metabolic  control  according  to  the  ESGSD  I4 had
he worst  height-for-age  Z-scores.  The  pathophysiology  of
hort stature  in  GSDI  has  yet  to  be  elucidated,  but  studies
onducted since  2008  have  shown  that  good  metabolic  con-
rol can  improve  growth.17,18 Hormonal  changes,  variation  in
lood pH  (due  to  metabolic  acidosis),  and  hyperlactatemia
ay contribute  to  this  growth  deﬁcit.  According  to  the
SGSD I  criteria,5 half  of  all  patients  in  the  present  sample
ad good  metabolic  control  of  their  condition,  even  though
ome had  BMI  Z-scores  >  2  SDs,  which  may  account  at  least
n part  for  the  near-adequate  growth  of  this  population  (18
f  21  patients  had  height-for-age  Z-scores  >  -2  SDs).
The  purpose  of  dietary  management  of  GSDI  is  to  mimic
ndogenous glucose  production.  Exogenous  dextrose  admin-
stration strategies  for  maintenance  of  normoglycemia  have
een assessed  and  modiﬁed  in  recent  years.  Frequent  meals
ontaining partially  cooked  starch,  continuous  nocturnal
astric drip  feeding  (CNGDF)  of  dextrose  via  nasogastric
ube, and  uncooked  cornstarch  (UCCS)  therapy  are  some  of
he available  strategies.  None  of  the  patients  in  this  case
eries were  on  continuous  nocturnal  feeding;  all  were  on
ncooked cornstarch  therapy  (ﬁve  to  six  doses  per  24  h,
ncluding overnight).  A  recent  meta-analysis15 compared
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everal  studies  of  UCCS  (diurnal  and  nocturnal)  with  stud-
es of  CNGDF,  and  found  both  short-term  and  long-term
mprovement of  metabolic  control  in  patients  given  UCCS.19
herefore,  CNGDF  should  be  restricted  to  select  cases,  as
he inconvenience  of  use  of  a  feeding  pump  and  the  risk
f severe  hypoglycemia  in  case  of  abrupt  discontinuation
f feeding  (e.g.,  due  to  a  power  outage  or  pump  mal-
unction) do  not  outweigh  the  metabolic  control  beneﬁts
f intermittent  night-time  UCCS  administration.  A  modiﬁed
ornstarch formulation  (Glycosade®,  Vitaﬂo,  Nestlé  Health
utrition, Vevey,  Switzerland),  which  granted  the  Food  and
rug Administration  (FDA)  approval  in  2012,  is  an  alternative
hat may  allow  patients  to  sleep  through  the  night.20
The  hepatomegaly  observed  in  patients  with  GSDI  may
e the  result  of  glycogen  deposition  and  fatty  liver  dis-
ase secondary  to  increased  ﬂow  of  free  fatty  acids  from
he adipose  tissue  to  the  liver.21 Routine  liver  ultrasound
s a  noninvasive  diagnostic  modality  that  can  be  used  to
ssess long-term  treatment  success.  As  this  study’s  anal-
sis of  ultrasound  ﬁndings  was  based  on  a  chart  review,
perator variability  is  a  concern.  The  histology  of  hepatocel-
ular adenomas  in  GSDI  is  similar  to  that  of  adenomas  seen
n other  conditions.  Several  hypotheses  have  attempted  to
xplain the  development  of  adenomatous  changes,  such
s imbalances  in  glucagon-to-insulin  ratio,  cellular  glyco-
en overload,  and  proto-oncogene  activation.21 The  three
atients with  hepatic  adenomas  in  the  present  case  series
ere 16,  17,  and  25  years  old  (patients  5,  6,  and  10
espectively). Patients  5  and  6  had  poor  metabolic  control,
ith hyperuricemia  and  hypoglycemia  despite  low  triglyce-
ides and  near-normal  lactate  levels.  Patient  10,  the  oldest
atient in  this  sample,  also  had  inadequate  metabolic  con-
rol.
Hepatocellular adenomas  may  occur  in  22%  to  75%  of
dults with  GSDIa,  and  the  risk  of  malignant  transformation
s approximately  10%.21 As  most  patients  are  under  the  age
f 20,  a  low  incidence  of  adenomas  is  to  be  expected  in  this
opulation regardless  of  metabolic  control.  Thus  far,  there
re no  cases  of  hepatocarcinoma  in  this  series.
Of  the  nine  patients  in  whom  bone  density  scans
ere performed,  only  one  (patient  1)  had  low  bone  mass
or chronological  age  in  accordance  with  the  2008  Ofﬁ-
ial Position  Statement  of  the  Brazilian  Society  for  Bone
ensitometry.22 Several  mechanisms  have  been  suggested  to
xplain the  low  bone  mineral  density  observed  in  patients
ith GSDI:  persistent  acidosis,  urinary  calcium  loss  without
dequate replacement,  reduction  of  bone  matrix  (hypo-
lycemia leads  to  decreased  glycosylation  of  bone  matrix
roteins), and  changes  in  growth  hormone  (GH)  levels.18
urthermore,  many  patients  with  GSDI  exhibit  abnormal
ubertal growth,5 and  sex  steroids  play  a  major  role  in  bone
ormation, particularly  during  puberty.22 Some  issues  must
e taken  into  account  when  analyzing  bone  mineral  den-
ity in  children  and  adolescents,  such  as  bone  maturation,
ex, and  stage  of  puberty.23 Overall,  the  patients  assessed  in
his case  series  had  good  bone  mineral  density  despite  their
SDI.
Despite the  rarity  of  GSDI,  it  must  not  be  overlooked  byediatricians. The  agent  used  for  treatment  of  this  inborn
rror of  metabolism  is  readily  available  at  any  grocery  store
r supermarket.  Administration  of  cornstarch  as  a  nutraceu-
ical (food  used  for  medicinal  purposes)  to  GSDI  patientsSantos  BL  et  al.
eads  to  excessive  weight  gain  as  a  side  effect,  due  to  the
ttendant increase  in  total  carbohydrate  intake  and  prob-
bly due  to  relative  physical  inactivity  as  well.  No  studies
ave assessed  the  efﬁcacy  of  physical  exercise  in  patients
ith GSDI,  and  it  is  not  contraindicated.  Therefore,  physical
ctivity --  supported  by  a well-designed  dietary  prescription
hat takes  the  pre-  and  post-exercise  periods  into  account  --
ay  be  an  effective  strategy  for  the  control  of  weight  gain  in
atients whose  metabolic  control  is  otherwise  satisfactory.
Greater  awareness  of  this  disorder  among  pediatricians
hould aid  their  search  for  an  etiological  diagnosis  in  cases
f hypoglycemia,  hepatomegaly,  dyslipidemia,  and  short
tature that  might  otherwise  be  improperly  managed.  Early
iagnosis based  on  clinical  and  laboratory  ﬁndings  is  feasi-
le, easy,  and  affordable  even  where  access  to  specialty  care
s limited.  Nevertheless,  investment  in  centers  for  expert
olecular diagnosis  is  both  warranted  and  necessary,  as  the
se of  molecular  methods  practically  obviates  the  need  for
iver biopsy.  Early  treatment  can  be  instituted  at  any  health
ervice, does  not  require  any  complex  interventions,  and
ecreases the  risk  of  death,  mainly  by  preventing  severe
ypoglycemia. Adequately  treated  patients  can  lead  intel-
ectually and  socially  satisfying  lives  with  no  limitations
ther than  a  special  diet.
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